ARTICLE | Product Development
Doubling up on diabetes
Poxel's imeglimin acts on multiple organs with new MOA for diabetes combos
October 14, 2013 7:00 AM UTC
Poxel S.A. hopes imeglimin will become physicians' go-to oral therapy to combine with metformin in diabetes. Clinical data show it improves the activity of two affected organs, may be safer than targeted oral antidiabetics and has a unique mechanism of action that could provide efficacy benefits.
Three of the organ-specific defects in diabetes are excess glucose production by the liver, impaired glucose uptake in muscle and insufficient insulin secretion from the pancreas...